Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
The development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through wh...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-12-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/7/4/111 |
_version_ | 1818271082049699840 |
---|---|
author | Suzanne E. Edwards Chantal M. Morel Reinhard Busse Stephan Harbarth |
author_facet | Suzanne E. Edwards Chantal M. Morel Reinhard Busse Stephan Harbarth |
author_sort | Suzanne E. Edwards |
collection | DOAJ |
description | The development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through which industry has an important influence on antibiotic consumption and where agreements can be made alongside financial incentives, even those intended to stimulate very early research. As long as the traditional unit sale-based business model for antibiotics remains in place, profit-making incentives will likely undermine efforts to sell and utilize antibiotics in a sustainable manner. In the short-term, while we try to come to a consensus on how best to fix the market, we need measures to prevent major over-selling and inappropriate promotion—especially for new, badly needed antibiotics that reach the market. This paper explores ways in which the pharmaceutical industry could help buttress sustainable antibiotic use while we search for more long-term, constructive, mutually-beneficial ways to organize the market. |
first_indexed | 2024-12-12T21:20:31Z |
format | Article |
id | doaj.art-5850189e2d0145a78f68c21139e9dc98 |
institution | Directory Open Access Journal |
issn | 2079-6382 |
language | English |
last_indexed | 2024-12-12T21:20:31Z |
publishDate | 2018-12-01 |
publisher | MDPI AG |
record_format | Article |
series | Antibiotics |
spelling | doaj.art-5850189e2d0145a78f68c21139e9dc982022-12-22T00:11:35ZengMDPI AGAntibiotics2079-63822018-12-017411110.3390/antibiotics7040111antibiotics7040111Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?Suzanne E. Edwards0Chantal M. Morel1Reinhard Busse2Stephan Harbarth3Department of Health Care Management, Berlin University of Technology, Straße des 17. Juni 135, 10623 Berlin, GermanyInfection Control Programme, WHO Collaborating Centre, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, SwitzerlandDepartment of Health Care Management, Berlin University of Technology, Straße des 17. Juni 135, 10623 Berlin, GermanyInfection Control Programme, WHO Collaborating Centre, University of Geneva Hospitals and Faculty of Medicine, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, SwitzerlandThe development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through which industry has an important influence on antibiotic consumption and where agreements can be made alongside financial incentives, even those intended to stimulate very early research. As long as the traditional unit sale-based business model for antibiotics remains in place, profit-making incentives will likely undermine efforts to sell and utilize antibiotics in a sustainable manner. In the short-term, while we try to come to a consensus on how best to fix the market, we need measures to prevent major over-selling and inappropriate promotion—especially for new, badly needed antibiotics that reach the market. This paper explores ways in which the pharmaceutical industry could help buttress sustainable antibiotic use while we search for more long-term, constructive, mutually-beneficial ways to organize the market.https://www.mdpi.com/2079-6382/7/4/111antibioticsantimicrobial resistanceantibiotic consumptionmarketingpromotionpharmaceutical industryresearch and development incentiveshealth economicssustainable use |
spellingShingle | Suzanne E. Edwards Chantal M. Morel Reinhard Busse Stephan Harbarth Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? Antibiotics antibiotics antimicrobial resistance antibiotic consumption marketing promotion pharmaceutical industry research and development incentives health economics sustainable use |
title | Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? |
title_full | Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? |
title_fullStr | Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? |
title_full_unstemmed | Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? |
title_short | Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry? |
title_sort | combatting antibiotic resistance together how can we enlist the help of industry |
topic | antibiotics antimicrobial resistance antibiotic consumption marketing promotion pharmaceutical industry research and development incentives health economics sustainable use |
url | https://www.mdpi.com/2079-6382/7/4/111 |
work_keys_str_mv | AT suzanneeedwards combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry AT chantalmmorel combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry AT reinhardbusse combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry AT stephanharbarth combattingantibioticresistancetogetherhowcanweenlistthehelpofindustry |